Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for FBIO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2010. Start Trial.
Date Value
June 30, 2026 46.07M
March 31, 2026 48.91M
December 31, 2025 65.09M
September 30, 2025 66.16M
June 30, 2025 67.08M
March 31, 2025 72.08M
December 31, 2024 73.34M
September 30, 2024 69.02M
June 30, 2024 85.94M
March 31, 2024 82.04M
December 31, 2023 82.14M
September 30, 2023 67.74M
June 30, 2023 78.60M
March 31, 2023 120.08M
December 31, 2022 124.90M
September 30, 2022 123.14M
June 30, 2022 116.88M
March 31, 2022 116.59M
December 31, 2021 72.87M
September 30, 2021 90.14M
June 30, 2021 96.97M
March 31, 2021 96.20M
December 31, 2020 87.23M
September 30, 2020 74.25M
June 30, 2020 109.23M
Date Value
March 31, 2020 109.04M
December 31, 2019 108.37M
September 30, 2019 108.18M
June 30, 2019 108.21M
March 31, 2019 107.87M
September 30, 2018 84.26M
June 30, 2018 84.03M
March 31, 2018 86.10M
December 31, 2017 66.51M
September 30, 2017 63.62M
June 30, 2017 46.95M
March 31, 2017 33.03M
December 31, 2016 28.22M
September 30, 2016 27.40M
June 30, 2016 21.80M
March 31, 2016 20.75M
December 31, 2015 23.17M
September 30, 2015 23.29M
June 30, 2015 23.23M
March 31, 2015 24.01M
December 31, 2014 14.01M
September 30, 2014 14.01M
June 30, 2014 14.01M
March 31, 2014 14.01M
December 31, 2013 13.62M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Inovio Pharmaceuticals, Inc. 5.103M
Ironwood Pharmaceuticals, Inc. 393.58M
Kura Oncology, Inc. 23.16M
Spero Therapeutics, Inc. 0.043M
Cue Biopharma, Inc. 7.179M